HIV vaccine (novel mosaic vaccine)  കാത്തിരുന്ന ആ സന്തോഷ വാർത്ത ...?!
Channel: YES 2 POSITIVE -Sexually Transmitted Diseases STDs
Date: 09/07/2021

The University of Oxford has launched a Phase I trial of a novel mosaic vaccine targeting a ‘broad range’ of HIV variants.

The HIV-CORE 0052 trial, part of the European Aids Vaccine Initiative, will involve 13 healthy HIV-negative adults aged 18 to 65 years old who are not considered to be at a high risk of infection.

The participants will receive one dose of the vaccine – known as the HIVconsvX vaccine – followed by a further boost dose at four weeks.